• Cylene Pharmaceuticals Inc., of San Diego, said it entered an exclusive, worldwide option and license agreement allowing TetraGene LLC, of Tucson, Ariz., to advance the development of Quarfloxin and Cylene's associated cancer quadruplex-targeting technologies.